First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors

Auteurs

C. Willemien Menke-van der Houven van Oordt, Carlos Gomez-Roca, Carla van Herpen, Andrew L. Coveler, Devalingam Mahalingam, Henk M. W. Verheul, Winette T. A. van der Graaf, Randolph Christen, Dominik Rüttinger, Stefan Weigand, Michael A. Cannarile, Florian Heil, Michael Brewster, Antje-Christine Walz, Tapan K. Nayak, Ernesto Guarin, Valerie Meresse, Christophe Le Tourneau